1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Kilian Kelly from Cynata Therapeutics (ASX: CYP) discusses Australia's federal funding boost of $238M for regenerative therapies. He says this initiative is a great chance for small firms to leverage funding, expertise, and infrastructure to develop scalable stem cell therapies. The funding represents one of the most substantial investments in Australia's biotechnology and advanced manufacturing sectors in recent years and positions Australia to become a global leader in regenerative medicine manufacturing.
On Cynata, Kilian highlights its ongoing clinical trials, including phase two for acute graft versus host disease with global centres and phase three for osteoarthritis, partnering with the University of Sydney. Results could pave the way for transformative treatments.
Kilian outlines the strategic financial status of Cynata, noting external grant funding covers key trials, with $8.5M in cash ensuring progress through next year. Kilian sees these developments enhancing Australia's biotech manufacturing.
